Evidence map›Paper›PMID 40151130›Full record

Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025

Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial.

Nima Vaziri, Gholamreza Dehghannoudeh, Fariba Sharififar, Fatemeh Dabaghzadeh, Farhad Sarafzadeh, Bizhan Ahmadi

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nima VaziriHerbal and Traditional Medicines Research Center, Kerman University of Medical Sciences, Kerman 761, Iran.
Gholamreza DehghannoudehPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman 761, Iran.
Fariba SharififarHerbal and Traditional Medicines Research Center, Kerman University of Medical Sciences, Kerman 761, Iran.
Fatemeh DabaghzadehPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman 761, Iran.
Farhad SarafzadehTropical and Infectious Diseases Research Center, Faculty of Medicine, Kerman University of Medical Sciences, Kerman 761, Iran.
Bizhan AhmadiGastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman 761, Iran.

Funding

Kerman University of Medical Sciences Project: Evaluating the Effects of Marmotti (Salvia mirzayanii Rech. f. & Esfand) Capsules as Adjunctive Treatment in Patients with Helicobacter Pylori Infection 98000128
6 · The paper itself

Abstract

objectiveTo evaluate the effect of this plant as adjunctive therapy on

methodsThe plant capsules were prepared and their physicochemical properties were assessed. In this clinical trial, 99 patients with

resultsH. pylori eradication rate of all the randomized participants was 59.59%. The eradication rate of

conclusionThe use of

Indexed as

Anti-Bacterial AgentsDrugs, Chinese HerbalHelicobacter InfectionsAdultAgedClarithromycinDrug Therapy, CombinationFemaleHelicobacter pyloriHumansMaleMiddle AgedTreatment OutcomeYoung AdultAnti-Bacterial AgentsClarithromycinDrugs, Chinese Herbalclarithromycin-based triple therapyRech. f. & Esfandresistance

Identifiers

PMID40151130
PMCPMC11955750

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.